Loading...
01/11 04:04
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlighted several positive aspects, including reduced net loss, improved adjusted EBITDA, and increased gross margin targets. The Q&A revealed optimism around biotech funding and expanding customer base in large pharma, despite some uncertainties. The company's strategic initiatives like RUO+ and efficiency improvements are promising. Although there were some evasive responses, the overall sentiment is positive, with strong growth in 75% of the business. The reaffirmed revenue guidance and gross margin improvements suggest a positive stock price movement in the short term.
Revenue Revenue was $10.5 million, a 9% increase from $9.6 million in the third quarter of 2024. The growth was driven by strong sales from the catalog portion of Lab Essentials products.
Lab Essentials Revenue Lab Essentials revenue was $8.3 million in the third quarter of 2025, a 16% increase from $7.2 million in the third quarter of 2024. The increase was attributable to higher average revenue per customer and a larger number of customers.
Clinical Solutions Revenue Clinical Solutions revenue was $1.7 million in the third quarter of 2025, a 13% decrease from $2.0 million in the third quarter of 2024. The decrease was due to lower average revenue per customer, partially offset by an increased number of customers.
Gross Profit Gross profit for the third quarter of 2025 was $3.2 million compared to $0.1 million in the third quarter of 2024. The increase was primarily driven by $2.8 million of nonrecurring and noncash charges in the third quarter of 2024 related to inventory disposal and write-downs.
Gross Margin Gross margin for the third quarter of 2025 was 30.7%, up from 0.9% in the third quarter of 2024. Excluding nonrecurring charges, gross margin in the third quarter of 2024 would have been 29.8%. The improvement was driven by higher revenue.
Operating Expenses Operating expenses for the third quarter of 2025 were $7.2 million compared to $7.5 million for the third quarter of 2024. The decrease was driven by a net reduction in general and administrative spending.
Net Loss Net loss for the third quarter of 2025 was $4.3 million or negative $0.08 per diluted share compared to a net loss of $7.6 million or negative $0.15 per diluted share for the third quarter of 2024.
Adjusted EBITDA Adjusted EBITDA was negative $1.6 million for the third quarter of 2025 compared to negative $2.2 million for the third quarter of 2024, excluding the impact of the $2.8 million charge related to inventory.
Capital Expenditures Capital expenditures for the third quarter of 2025 were $0.4 million compared to $0.3 million in the third quarter of 2024.
Free Cash Outflow Free cash outflow was $2.4 million for the third quarter of 2025, the same as the third quarter of 2024.
Cash and Borrowings As of September 30, 2025, the company had $22.1 million in cash, cash equivalents, and short-term investments, and $13.2 million in total borrowings.
Lab Essentials Revenue Growth: Revenue from Lab Essentials products grew 16% year-over-year, driven by higher average revenue per customer and an increased number of customers.
Clinical Solutions Revenue Decline: Revenue from Clinical Solutions products decreased by 13% year-over-year due to lower average revenue per customer, despite an increased number of customers.
Market Exposure: 75% of revenue comes from catalog products and custom products across various market segments, which grew in low double digits. However, 25% of revenue is derived from biopharma customers, which is impacted by delays in biotech funding and clinical trials.
Operational Efficiency Projects: Key projects such as electronic batch records, high-throughput dispensing automation, and larger batch size capabilities are on track for 2026, aiming to reduce costs and improve efficiency.
On-Time Delivery Improvement: Investments in operational metrics have led to improved on-time delivery, differentiating Teknova from competitors.
Revenue Scaling Strategy: Teknova aims to scale to over $200 million in annualized revenue without significant additional capital investments.
Acquisition and Collaboration Plans: The company is actively pursuing tuck-in acquisitions and collaborations to enhance capabilities and accelerate growth.
Biotech Funding Environment: Approximately 25% of total revenue is derived from purchases of custom products by biopharma customers, which are affected by changes in biotech funding levels. Continued delays in larger purchases of custom products have been observed, and unless there is sustained improvement in biotech funding or advancement through clinical trials, only modest improvement is expected in this market in 2026.
Clinical Solutions Revenue Decline: Revenue from Clinical Solutions products decreased by 13% compared to the previous year, driven by lower average revenue per customer. This decline is attributed to the addition of newer customers who typically order less and the lumpiness in revenue due to larger average order sizes.
Macroeconomic Sensitivity: The company’s gross margins are highly sensitive to fluctuations in cost categories due to the size of the business. This sensitivity could impact financial performance in the face of unfavorable macroeconomic conditions.
Operating Expenses and Profitability: Operating expenses remain high, and the company is not yet adjusted EBITDA positive. Achieving profitability is contingent on reaching $50 million to $55 million in annualized revenue, which may be challenging given current market conditions.
Dependence on U.S. Market: The company has limited exposure to international markets, with most sales concentrated in the U.S. This lack of diversification could pose risks if domestic market conditions deteriorate.
Revenue Guidance for 2025: The company reiterates its 2025 total revenue guidance of $39 million to $42 million, expecting to finish slightly below the midpoint of that range due to persistent softness in demand for Clinical Solutions products from biopharma customers.
Growth Expectations for 2026: Modest growth is expected in custom biopharma products, representing about 25% of total revenue, and low double-digit growth in the remaining 75% of total revenue, which is less impacted by the weak biotech funding environment.
Gross Margin Target for 2025: Gross margin target for fiscal year 2025 remains in the low 30s, with approximately 70% of incremental revenue expected to flow through to gross profit over longer periods.
Operating Expenses and Investment Plans: Operating expenses are expected to be at least $8 million in the fourth quarter of 2025, with a moderate increase in sales and marketing investments to position for broader market recovery.
Free Cash Outflow for 2025: The company expects free cash outflow of less than $12 million for the full year 2025.
Adjusted EBITDA Positive Target: The company believes it will become adjusted EBITDA positive in the range of $50 million to $55 million in annualized revenue.
Long-term Revenue Scaling Potential: The company is confident in its ability to scale to more than $200 million in annualized revenue without significant additional capital investments.
Market Trends and Biopharma Funding: Unless there is sustained improvement in the biotech funding environment or advancement through clinical trials of supported therapies, only modest improvement in the biopharma end market is expected in 2026.
The selected topic was not discussed during the call.
The earnings call highlights strong financial performance with increased EBITDA, improved margins, and reduced net debt. Despite higher share-based compensation costs, the company maintains stable corporate costs. The Q&A session reveals cautious optimism, with a focus on debt reduction and strategic planning. While some management responses lacked detail, the overall sentiment is positive due to strong earnings and improved financial metrics, suggesting a likely stock price increase.
The earnings call highlighted several positive aspects, including reduced net loss, improved adjusted EBITDA, and increased gross margin targets. The Q&A revealed optimism around biotech funding and expanding customer base in large pharma, despite some uncertainties. The company's strategic initiatives like RUO+ and efficiency improvements are promising. Although there were some evasive responses, the overall sentiment is positive, with strong growth in 75% of the business. The reaffirmed revenue guidance and gross margin improvements suggest a positive stock price movement in the short term.
The earnings call summary and Q&A indicate a positive sentiment. The company has improved financial performance with higher revenue and reduced expenses. The Q&A reveals strong growth in essential reagents and catalog business, proactive marketing efforts, and promising gross margin outlook. Despite some challenges in biopharma spending and customer spend predictability, the company is well-positioned with strong growth initiatives, including RUO+ and inorganic opportunities. The overall sentiment is positive, with a potential stock price increase of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
